- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07567443
A1-Free vs. Conventional Milk Metabolic Response Study
A Randomized Crossover Study Evaluating Postprandial Glucose and Insulin Responses to A1-Free and Conventional Milk With and Without a Delayed Lactose Challenge in Healthy Adults
This study will examine how different types of milk affect blood sugar and insulin responses after eating. Specifically, the study compares milk that contains only A2 beta-casein protein (A1-free milk) to conventional milk, which contains both A1 and A2 proteins.
Participants will complete four study visits in which they will consume different milk-based beverages. These include lactose-containing milk and lactose-free milk followed by a lactose drink given later. Blood samples will be collected over several hours to measure glucose and insulin responses. Breath tests and questionnaires will also be used to assess digestion and gastrointestinal symptoms.
The goal of this study is to determine whether milk protein type influences metabolic responses and whether consuming lactose-free milk affects how the body processes lactose when it is consumed later.
Studieoversigt
Status
Detaljeret beskrivelse
Postprandial glucose and insulin responses are important indicators of metabolic health, even in individuals without diagnosed metabolic disease. The rate and pattern of nutrient digestion and absorption can influence these responses, and emerging evidence suggests that differences in milk protein composition, specifically the presence or absence of A1 beta-casein, may alter gastrointestinal function and metabolic outcomes.
This study is a randomized, double-blind, crossover trial designed to evaluate the effects of A1-free milk compared to conventional milk on postprandial metabolic responses in healthy adults. Participants will complete four experimental conditions in random order: (1) lactose-containing A1-free milk, (2) lactose-containing conventional milk, (3) lactose-free A1-free milk followed by a delayed lactose challenge, and (4) lactose-free conventional milk followed by a delayed lactose challenge.
The inclusion of both lactose-containing and lactose-free conditions allows for evaluation of two complementary questions. First, direct comparisons between lactose-containing A1-free and conventional milk will assess whether milk protein composition influences postprandial glucose and insulin responses under typical consumption conditions. Second, the lactose-free preload conditions, combined with a standardized delayed lactose challenge, are designed to evaluate whether prior milk consumption modifies subsequent metabolic responses to lactose exposure. This approach provides insight into potential differences in digestive kinetics, including gastric emptying, nutrient delivery, and lactose digestion and absorption.
During each study visit, participants will consume a standardized milk-based intervention following an overnight fast. In the lactose-free conditions, a lactose beverage matched to the amount of lactose typically present in the milk will be administered 60 minutes after milk consumption. Blood samples will be collected at multiple timepoints over a postprandial period to measure glucose and insulin concentrations and characterize response patterns, including early-phase responses and overall exposure.
Secondary and exploratory outcomes include breath hydrogen testing as a non-invasive marker of carbohydrate fermentation and lactose maldigestion, as well as gastrointestinal symptom assessments using validated questionnaires. These measures will be used to provide additional context for interpreting metabolic responses across conditions.
The crossover design allows each participant to serve as their own control, improving statistical power and reducing variability. The findings from this study will help clarify whether differences in milk protein composition influence metabolic responses and whether prior exposure to lactose-free milk alters the body's handling of lactose consumed at a later time.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Laura A Robinson, PhD
- Telefonnummer: 908-442-3688
- E-mail: ldelvers@purud.edu
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Ability/desire to provide informed consent
- Are between 18 and 65 years of age
- Are generally healthy, with no known metabolic or gastrointestinal conditions that would affect digestion or metabolism
- Are willing to consume milk-based beverages and lactose-containing drinks as part of the study
- Are willing to fast overnight (approximately 10-12 hours) prior to study visits and follow study instructions (e.g., diet and activity restrictions)
- Are willing to attend all study visits and complete all study procedures (blood draws, breath tests, urine samples, questionnaires)
- Are able to understand and provide written informed consent in English.
Exclusion Criteria:
- You have a known allergy to milk or dairy products
- You are currently pregnant, planning to become pregnant, or breastfeeding
- You currently smoke or have used tobacco or nicotine-containing products within the past 3 months
- You have a history of excessive alcohol use within the past 30 days
- You have been diagnosed with diabetes (Type 1 or Type 2), prediabetes, or other metabolic conditions that affect glucose or insulin responses (such as insulin resistance, metabolic syndrome, or polycystic ovary syndrome [PCOS])
- You have a history of gastrointestinal conditions that may affect digestion or absorption (such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, or severe irritable bowel syndrome)
- You have had gastrointestinal surgery that alters normal digestive function (such as bariatric surgery or gastric bypass)
- You have other medical conditions that may affect digestion or interfere with study results (such as Past or present: Organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, chronic constipation, diverticulosis, inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), small intestine bacterial overgrowth syndrome (SIBO), gastroparesis, gastro-esophageal reflux disease (GERD), Irritable Bowel Syndrome (IBS) or any other medical condition with symptoms that could confound collection of adverse events.)
- You have used medications or supplements known to affect glucose metabolism, digestion, or gastrointestinal function within the following timeframes prior to enrollment:
- Within 4 weeks: insulin, metformin, GLP-1 receptor agonists, corticosteroids, digestive enzymes, fiber supplements, and all oral or IV antibiotics
- Within 2 weeks: bismuth-containing compounds (e.g., Pepto-Bismol) and proton pump inhibitors or acid suppressors (e.g., omeprazole [Prilosec], lansoprazole [Prevacid], esomeprazole [Nexium], pantoprazole [Protonix], rabeprazole [Aciphex])
- Within 1 week: laxatives and stool softeners (e.g., Miralax, Colace, senna, lactulose, Citrucel, Metamucil, Fibercon), probiotics and prebiotics, gastrointestinal motility agents (e.g., Reglan, Linzess, Amitiza), and antidiarrheal medications (e.g., loperamide [Imodium], Lomotil)
- You have had a recent infection within the past 30 days
- You have been diagnosed with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C
- You are currently undergoing chemotherapy
- Height: ___ Weight: ___ BMI: ___ Weighing <16.5 kg or Body mass index > 35 kg/m2
- You have participated in another clinical trial or used an investigational product within the past 30 days
- You have any other condition that, as determined by the study team, would make participation unsafe or interfere with study results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Lactose-Containing A1-Free Milk
Participants consume lactose-containing A1-free milk during one study visit.
Blood, breath hydrogen, urine, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
|
A lactose-containing milk beverage containing A2 beta-casein and no A1 beta-casein, consumed during one experimental study visit.
Andre navne:
|
|
Eksperimentel: Lactose-Containing Conventional Milk
Participants consume lactose-containing conventional milk containing both A1 and A2 beta-casein during one study visit.
Blood, breath hydrogen, urine, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
|
A lactose-containing conventional milk beverage containing both A1 and A2 beta-casein, consumed during one experimental study visit.
Andre navne:
|
|
Eksperimentel: Lactose-Free A1-Free Milk With Delayed Lactose Drink
Participants consume lactose-free A1-free milk followed by a lactose drink administered 60 minutes after milk consumption.
Blood, breath hydrogen, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
|
A lactose-free A1-free milk beverage consumed at the start of the study visit, followed by a lactose drink administered 60 minutes after milk consumption.
The lactose drink is matched to the amount of lactose expected in the milk serving.
|
|
Eksperimentel: Lactose-Free Conventional Milk With Delayed Lactose Drink
Participants consume lactose-free conventional milk containing both A1 and A2 beta-casein followed by a lactose drink administered 60 minutes after milk consumption.
Blood, breath hydrogen, and gastrointestinal symptom measures are collected over the 180 minute postprandial period.
|
A lactose-free conventional milk beverage containing both A1 and A2 beta-casein consumed at the start of the study visit, followed by a lactose drink administered 60 minutes after milk consumption.
The lactose drink is matched to the amount of lactose expected in the milk serving.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postprandial Plasma Insulin Incremental Area Under the Curve (iAUC)
Tidsramme: 0 to 180 minutes post-intervention during each study visit
|
Incremental area under the curve (iAUC) for plasma insulin concentrations following consumption of each study condition, measured from serial blood samples collected via an indwelling catheter.
|
0 to 180 minutes post-intervention during each study visit
|
|
Postprandial Plasma Glucose Incremental Area Under the Curve (iAUC)
Tidsramme: 0 to 180 minutes post-intervention during each study visit
|
Incremental area under the curve (iAUC) for plasma glucose concentrations following consumption of each study condition, measured from serial blood samples collected via an indwelling catheter.
|
0 to 180 minutes post-intervention during each study visit
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Early-Phase Postprandial Glucose and Insulin Response
Tidsramme: 0 to 60 minutes post-intervention
|
Early-phase postprandial response assessed by incremental area under the curve (iAUC) for plasma glucose and insulin concentrations.
|
0 to 60 minutes post-intervention
|
|
Time to Peak Plasma Glucose and Insulin Concentrations (Tmax)
Tidsramme: 0 to 180 minutes post-intervention
|
Time required to reach peak plasma glucose and insulin concentrations following each study condition.
|
0 to 180 minutes post-intervention
|
|
Circulating Metabolite Responses
Tidsramme: 0, 30, 60, and 120 minutes
|
Postprandial changes in circulating metabolites, including amino acids and acylcarnitines, measured from plasma samples to assess metabolic responses.
|
0, 30, 60, and 120 minutes
|
|
Breath Hydrogen Concentrations
Tidsramme: Baseline and every 30 minutes from 0 to 180 minutes post-intervention
|
Breath hydrogen levels measured as a non-invasive marker of carbohydrate fermentation and lactose maldigestion.
|
Baseline and every 30 minutes from 0 to 180 minutes post-intervention
|
|
Gastrointestinal Symptom Scores
Tidsramme: Baseline and at 60, 120, and 180 minutes post-intervention
|
Self-reported gastrointestinal symptoms (e.g., bloating, gas, abdominal discomfort) assessed using visual analog scale and Likert-type questionnaires.
|
Baseline and at 60, 120, and 180 minutes post-intervention
|
|
Urinary Galactose Concentrations
Tidsramme: Baseline and 180 minutes post intervention
|
Urinary galactose concentrations measured as an marker of lactose metabolism.
|
Baseline and 180 minutes post intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Dennis A Savaiano, PhD, Purdue University
Publikationer og nyttige links
Generelle publikationer
- Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004 Nov;80(5):1246-53. doi: 10.1093/ajcn/80.5.1246.
- Gunnerud U, Holst JJ, Ostman E, Bjorck I. The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot- study of bovine and human milk. Nutr J. 2012 Oct 12;11:83. doi: 10.1186/1475-2891-11-83.
- Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol. 2015 Feb;11(2):112-28. doi: 10.1038/nrendo.2014.202. Epub 2014 Nov 25.
- Shrestha A, Samuelsson LM, Sharma P, Day L, Cameron-Smith D, Milan AM. Comparing Response of Sheep and Cow Milk on Acute Digestive Comfort and Lactose Malabsorption: A Randomized Controlled Trial in Female Dairy Avoiders. Front Nutr. 2021 Feb 15;8:603816. doi: 10.3389/fnut.2021.603816. eCollection 2021.
- Ramakrishnan M, Zhou X, Dydak U, Savaiano DA. Gastric Emptying of New-World Milk Containing A1 and A2 Beta-Casein Is More Rapid as Compared to Milk Containing Only A2 Beta-Casein in Lactose Maldigesters: A Randomized, Cross-Over Trial Using Magnetic Resonance Imaging. Nutrients. 2023 Feb 4;15(4):801. doi: 10.3390/nu15040801.
- Sun L, Tan KWJ, Han CMS, Leow MK, Henry CJ. Impact of preloading either dairy or soy milk on postprandial glycemia, insulinemia and gastric emptying in healthy adults. Eur J Nutr. 2017 Feb;56(1):77-87. doi: 10.1007/s00394-015-1059-y. Epub 2015 Oct 6.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- IRB 2026-00000555
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Postprandial metabolisme
-
Northumbria UniversityAfsluttetAppetit | Postprandial glykæmi, | Postprandial insulinæmiDet Forenede Kongerige
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; CAPES Foundation...Aktiv, ikke rekrutterendeSundhed | Postprandial metabolisme | Galdesyresynteseforstyrrelser | Postprandial lipidmetabolismeBrasilien
-
University of Sao PauloThe São Paulo Research Foundation (FAPESP); CAPES Foundation - Ministry...Aktiv, ikke rekrutterendePost-prandial glykæmisk respons | Postprandial metabolisme | Postprandial lipidmetabolismeBrasilien
-
Solvay PharmaceuticalsAfsluttetPostprandial oppustethed | Postprandial bøvsen | Postprandial EruktionForenede Stater
-
San Diego State UniversityAfsluttetPostprandial hyperglykæmi | Postprandial glykæmisk respons | Postprandial insulinForenede Stater
-
University of AarhusArla FoodsAfsluttetPostprandial lipidmetabolismeDanmark
-
Hospital de Santo EspíritoEuropean UnionAfsluttet
-
University of TurkuAfsluttet
-
Lund UniversitySwedish Foundation for Strategic ResearchAfsluttet
-
University of TurkuAfsluttetPostprandial glykæmiFinland